SUBLINGUAL SEMAGLUTIDE
WHAT IS SUBLINGUAL SEMAGLUTIDE
Semaglutide belongs to a class of medications known as GLP-1 receptor agonists, which mimic the action of a natural hormone involved in glucose regulation. Its efficacy in controlling blood glucose levels and promoting weight loss has positioned it as a game-changer in the treatment landscape of type 2 diabetes and obesity.
The traditional modes of administration, primarily through injections, have posed barriers to some patients, leading to the exploration of more patient-friendly alternatives.
THE CHALLENGES OF INJECTABLE MEDICATIONS
Semaglutide, a GLP 1 receptor agonist initially approved for the treatment of type 2 diabetes, has demonstrated significant weight loss efficacy in injectable form.
Many patients would prefer to avoid any injectable medications if it’s possible and would go for oral drugs, however, the oral tablets of semaglutide showed extremely low absorption of the drug.
The development of a sublingual semaglutide formulation and the innovative SubMagna™ delivery system solved this issue and holds promise for enhancing patient adherence and outcomes in weight management.
THE SCIENCE BEHIND SUBLINGUAL SEMAGLUTIDE
The sublingual formulation uses SubMagna™ delivery system technology which is a self-emulsifying, anhydrous vehicle that enhances permeation of Semaglutide.
Upon administration of the formulation sublingually, the drug forms an emulsion with saliva which greatly enhances its solubility and absorption of the active ingredient (Semaglutide).